News

July 10, 2015 10:30 am
Having myeloma is undeniably expensive. But will new systems of evaluating the cost and efficacy of treatment end up harming myeloma patients by mandating suboptimal care and eliminating access to needed drugs? In his blog this week, IMF Chairman...

Pages